Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014738 | 1.00 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20213565 | 0.87 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL30014711 | 0.87 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20213481 | 0.86 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL18367189 | 0.85 | RIPK1 (0.76) | RIPK1 | |
| SCHEMBL20221905 | 0.83 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL18367185 | 0.81 | RIPK1 (0.74) | RIPK1 | |
| SCHEMBL20228819 | 0.80 | RIPK1 (0.74) | RIPK1 | |
| SCHEMBL20221909 | 0.78 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20228796 | 0.75 | RIPK1 (0.65) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071721-B2 | Bicyclic amide compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-10933036-B2 | — | — | 2021-03-02 | — | — | US | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| WO-2018100070-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-07 | — | — | WO | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | CYP4B1, CYP1B1, AADAC | RIPK1 4061/4885 |
| US-11071721-B2 | Bicyclic amide compounds and methods of use thereof | CYP4B1, CYP1B1, AADAC | RIPK1 4061/4885 |
| US-10933036-B2 | — | CYP1B1, CYP4B1, CYP11B2 | RIPK1 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.